Antibody therapy has emerged as one of the most promising treatment advances for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), marking a fundamental shift away from symptom management toward targeting the underlying biology that causes these neurodegenerative diseases. FDA-approved anti-amyloid antibodies now slow cognitive decline in Alzheimer’s patients by 20–35%, with brain imaging showing 60–80% reduction in amyloid plaques—the toxic protein clumps long believed central to the disease. For ALS, which has historically had almost no effective disease-modifying treatments, several antibody-based therapies are now advancing through clinical trials, targeting misfolded proteins like TDP-43 and SOD1. This article examines the current state of antibody therapy for both conditions, explores the clinical evidence behind these advances, discusses how patients might access these treatments, and outlines what remains on the horizon for these devastating neurological disorders.
The pace of development in this field is accelerating. As of early 2025, the Alzheimer’s drug pipeline includes 182 clinical trials for 138 different drugs, with 48 trials in late-stage Phase 3 testing. For ALS, multiple antibody programs are moving from preclinical work into human testing, something that was virtually unthinkable just five years ago. However, these advances come with important tradeoffs—including the risk of amyloid-related imaging abnormalities (brain microhemorrhages and microinfarcts) in Alzheimer’s therapies, and the challenge of delivering antibodies across the blood-brain barrier, which keeps out many large molecules trying to reach brain cells.
Table of Contents
- What Are Anti-Amyloid Antibodies and How Do They Work in Alzheimer’s Disease?
- Beyond Amyloid—Tau-Targeting Antibodies and Combination Approaches
- Antibody Therapy for ALS—Targeting Misfolded Protein Pathology
- Practical Considerations—Access, Cost, and Treatment Logistics
- The Dark Side—Amyloid-Related Imaging Abnormalities and Other Safety Concerns
- Early Detection Biomarkers—Catching Disease Before Symptoms
- The Road Ahead—What to Expect in Alzheimer’s and ALS Antibody Development
- Conclusion
What Are Anti-Amyloid Antibodies and How Do They Work in Alzheimer’s Disease?
Anti-amyloid antibodies are monoclonal antibodies—lab-made proteins designed to bind to and eliminate amyloid-beta, a sticky protein that accumulates in Alzheimer’s patients’ brains. Unlike earlier drugs that merely slowed amyloid buildup, these antibodies actively clear amyloid that’s already there. Several are now approved or in late-stage testing: lecanemab (Leqembi), aducanumab (Aduhelm), and donanemab (Kisunla) are either FDA-approved or under expedited review. When amyloid is removed from the brain, the thinking goes, the cascade of inflammation and neuronal death that follows might be halted or slowed.
The clinical data is striking compared to previous Alzheimer’s drugs. Anti-amyloid antibodies reduce amyloid plaques by 60–80% as measured on PET brain scans, and slow the rate of cognitive decline by 20–35% in early symptomatic disease—the best results ever seen in an Alzheimer’s trial. The catch is important: these drugs only work in the earliest stages of disease (mild cognitive impairment or mild dementia), and they require regular infusions or injections. Lecanemab, for example, requires an intravenous infusion every two weeks initially, though the FDA recently approved a subcutaneous maintenance dose (called Leqembi Iqlik) in August 2025 and filed a supplemental application for subcutaneous initiation dosing in September 2025, which could eventually make the treatment more convenient for patients.
Beyond Amyloid—Tau-Targeting Antibodies and Combination Approaches
While amyloid targeting has dominated the headlines, tau—another misfolded protein that tangles inside Alzheimer’s neurons—is an equally destructive pathology. Several tau-targeting antibodies are now in Phase 2 testing, with clinical data expected by the end of 2025 for drugs including E2814 (etalanetug), posdinemab, BMS-986446, and MK-2214. Early results suggest these may become powerful adjuncts to anti-amyloid therapy, potentially allowing doctors to attack the disease from two angles simultaneously. However, tau antibodies also carry risks. The blood-brain barrier is highly selective about what it lets through, and large antibody molecules have difficulty crossing it efficiently.
Some tau antibodies are being engineered with special tags that help them penetrate the brain—a technology called “Brainshuttle” that was used in trontinemab, a bispecific antibody currently in Phase 3 trials. In a Phase 1b/2a trial of 114 subjects, trontinemab achieved amyloid negativity in 91% of participants at 28 weeks, with only a <5% rate of brain hemorrhage or brain swelling—substantially lower than the 3–5% rates historically seen with other therapies. This represents meaningful progress in safety, though any risk of brain bleeding must be weighed carefully by patients and neurologists. Combination therapy is likely the future of Alzheimer's treatment. Just as cancer is now routinely treated with multiple drugs targeting different pathways, Alzheimer's disease may require combination anti-amyloid and anti-tau approaches, or even inclusion of anti-inflammatory agents to quell the neuroinflammation that these proteins trigger.
Antibody Therapy for ALS—Targeting Misfolded Protein Pathology
Amyotrophic lateral sclerosis has long been a therapeutic graveyard. For decades, the only approved drug was riluzole, which extends survival by a few months. Recently, however, researchers identified that ALS involves misfolded proteins—particularly TDP-43 and SOD1—that accumulate and damage motor neurons. This discovery opened the door to antibody-based approaches. Several antibody candidates are now in clinical development.
ATLX-1282, developed by Alchemab and licensed to Eli Lilly in a May 2025 deal worth up to $415 million, entered Phase 1 testing in September 2025. VTx-002, a vectorized antibody from VectorY that targets misfolded TDP-43, received FDA clearance for Phase 1/2 trials in December 2025 and Fast Track designation in January 2026—a regulatory designation meant to accelerate development of drugs addressing serious unmet needs. AP-101 from AL-S Pharma showed encouraging Phase 2 results, with significant extension of survival and delayed need for respiratory support compared to delayed treatment controls. PMN267, a humanized monoclonal antibody from ProMIS also targeting misfolded TDP-43, is in development. The diversity of approaches targeting different protein forms and epitopes suggests the field is taking a portfolio approach—testing multiple shots on goal—rather than betting everything on a single mechanism.
Practical Considerations—Access, Cost, and Treatment Logistics
Getting access to anti-amyloid antibodies for Alzheimer’s remains challenging. Patients must first have either a confirmed diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (typically confirmed by amyloid PET scanning or spinal fluid biomarkers), and the disease must be caught early enough that cognition is only mildly affected. Lecanemab requires a dose escalation phase lasting about 10 weeks, during which patients receive weekly or biweekly infusions, followed by biweekly maintenance dosing. This is a significant time commitment and requires access to an infusion center. Aducanumab and donanemab have different dosing schedules but similar logistical demands.
Cost is another barrier. Lecanemab costs approximately $26,500 per year out of pocket before insurance, though Medicare coverage was approved in January 2023. Insurance coverage for non-Medicare patients remains patchy and often requires prior authorization. The new subcutaneous formulations (like Leqembi Iqlik) promise to reduce some of this burden by allowing home administration, but this still requires training and regular medical supervision to monitor for amyloid-related imaging abnormalities. For ALS patients, treatment access will likely face similar hurdles once therapies are approved—these are complex biologics that will command high prices and require specialized monitoring.
The Dark Side—Amyloid-Related Imaging Abnormalities and Other Safety Concerns
Anti-amyloid antibody therapy carries real safety risks that must be respected. Amyloid-related imaging abnormalities (ARIA) encompass two phenomena: amyloid-related imaging abnormality-edema (ARIA-E), or brain swelling, and amyloid-related imaging abnormality-microhemorrhages (ARIA-H), or tiny brain bleeds. These occur in a subset of treated patients and can cause headache, vision changes, confusion, or difficulty with balance. In clinical trials, symptomatic ARIA occurred in roughly 10–20% of patients receiving anti-amyloid antibodies, though serious events requiring hospitalization are rare. Certain patients are at higher risk.
APOE4 carriers—people who have a genetic variant that increases Alzheimer’s risk—experience higher rates of ARIA than non-carriers. Patients on anticoagulants like warfarin or doacs face additional bleeding risk if ARIA-H occurs. Undiagnosed cerebral amyloid angiopathy (amyloid accumulation in blood vessel walls, which causes brain microhemorrhages independent of antibody treatment) is another risk factor. This is why neuroimaging and genetic testing are mandatory before starting anti-amyloid therapy, and why regular follow-up MRI scans are required during treatment. For ALS antibodies, the blood-brain barrier penetration challenge means toxins and off-target effects are less likely, but this hasn’t yet been fully tested in large trials.
Early Detection Biomarkers—Catching Disease Before Symptoms
One of the most exciting recent advances is the development of blood and spinal fluid biomarkers that can detect the misfolded proteins of ALS and frontotemporal dementia years before symptoms appear. These antibody-based tests can now identify individuals harboring irregular TDP-43 and SOD1 proteins who have no cognitive or motor symptoms yet.
This matters enormously: if antibody therapy is most effective when given early, before neuronal loss becomes irreversible, then identifying asymptomatic at-risk individuals could become transformative. This opens the door to preventive or presymptomatic treatment—a paradigm shift similar to what happened with cancer screening and statins for cardiovascular disease. However, it also raises ethical questions about labeling asymptomatic individuals as “diseased,” the psychological burden of knowing you have pathology without symptoms, and the fairness of access to expensive preventive treatments.
The Road Ahead—What to Expect in Alzheimer’s and ALS Antibody Development
The pipeline is robust and accelerating. In Alzheimer’s disease, tau-targeting antibodies will likely begin reaching patients by 2027, and combination therapy trials (anti-amyloid plus anti-tau) are already launching. Novel bispecific antibodies like trontinemab that can target both amyloid and tau, or hit amyloid and inflammation simultaneously, represent the next generation of design sophistication.
For ALS, multiple antibody programs will move into Phase 2 testing over the next 12–24 months, and it’s realistic to expect the first disease-modifying ALS antibody therapy to reach patients by 2027–2028, though likely not before multiple Phase 3 trials confirm efficacy. Technological improvements in blood-brain barrier penetration, in reducing off-target binding, and in engineering antibodies for longer half-lives will continue to make these therapies more practical and safer. The field is also shifting toward combination approaches—treating ALS with multiple antibodies targeting different misfolded proteins, much as we now treat cancer or HIV with polypharmacy. Whether these advances will translate into meaningful improvements in patients’ lives, rather than just biomarker improvements, remains to be rigorously tested.
Conclusion
Antibody therapy represents a sea change in how we approach Alzheimer’s disease and ALS. For Alzheimer’s, approved anti-amyloid antibodies now offer the first disease-slowing effect with meaningful clinical benefits, though they work only in early disease and carry real safety risks that require careful patient selection and monitoring. For ALS, antibody-based approaches are breaking the therapeutic drought and finally attacking the underlying disease mechanisms rather than just managing symptoms. The next frontier is tau-targeting antibodies for Alzheimer’s, combination therapies, and moving deeper into presymptomatic treatment.
If you or a loved one has been diagnosed with mild cognitive impairment or early Alzheimer’s disease, a conversation with a memory specialist or neurologist about anti-amyloid therapy is worth having—this is not symptom management, but genuine disease modification. For ALS patients, staying informed about clinical trial opportunities is critical, as several promising antibody therapies will likely reach patients within the next two to three years. Clinical trials are actively recruiting; organizations like the ALS Association (als.org) maintain registries of ongoing studies. The era of waiting for Alzheimer’s and ALS to progress is ending. The era of intervening early with targeted antibody therapy is beginning.
